PL3242947T3 - Terapia genowa i elektroporacja do leczenia zmian złośliwych - Google Patents

Terapia genowa i elektroporacja do leczenia zmian złośliwych

Info

Publication number
PL3242947T3
PL3242947T3 PL16735524T PL16735524T PL3242947T3 PL 3242947 T3 PL3242947 T3 PL 3242947T3 PL 16735524 T PL16735524 T PL 16735524T PL 16735524 T PL16735524 T PL 16735524T PL 3242947 T3 PL3242947 T3 PL 3242947T3
Authority
PL
Poland
Prior art keywords
malignancies
electroporation
treatment
gene therapy
therapy
Prior art date
Application number
PL16735524T
Other languages
English (en)
Polish (pl)
Inventor
Robert H. Pierce
Jocelyn H. Wright
Original Assignee
Oncosec Medical Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncosec Medical Incorporated filed Critical Oncosec Medical Incorporated
Publication of PL3242947T3 publication Critical patent/PL3242947T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL16735524T 2015-01-09 2016-01-08 Terapia genowa i elektroporacja do leczenia zmian złośliwych PL3242947T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562101850P 2015-01-09 2015-01-09
US201562126300P 2015-02-27 2015-02-27
PCT/US2016/012759 WO2016112359A1 (en) 2015-01-09 2016-01-08 Method for the treatment of malignancies
EP16735524.7A EP3242947B1 (en) 2015-01-09 2016-01-08 Gene therapy and electroporation for the treatment of malignancies

Publications (1)

Publication Number Publication Date
PL3242947T3 true PL3242947T3 (pl) 2021-01-11

Family

ID=56356515

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16735524T PL3242947T3 (pl) 2015-01-09 2016-01-08 Terapia genowa i elektroporacja do leczenia zmian złośliwych

Country Status (9)

Country Link
US (1) US20180000895A1 (enExample)
EP (2) EP3799879B1 (enExample)
JP (3) JP2018504403A (enExample)
CA (1) CA2973390A1 (enExample)
DK (1) DK3242947T3 (enExample)
ES (1) ES2809734T3 (enExample)
MX (1) MX383277B (enExample)
PL (1) PL3242947T3 (enExample)
WO (1) WO2016112359A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180000895A1 (en) * 2015-01-09 2018-01-04 Oncosec Medical Incorporated Method for the treatment of malignancies
DK3474760T3 (da) 2016-06-27 2023-03-20 Galvanize Therapeutics Inc Generator og et kateter med en elektrode til at behandle en lungepassage
US12403305B2 (en) 2016-06-27 2025-09-02 Galvanize Therapeutics, Inc. Immunostimulation in the treatment of viral infection
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
EP4552592A3 (en) 2017-12-26 2025-06-18 Galvanize Therapeutics, Inc. Optimization of energy delivery for various applications
KR102793500B1 (ko) * 2018-05-02 2025-04-14 그랜드 디케이드 디벨로프먼츠 리미티드 전기천공 시스템, 방법, 및 장치
WO2020033715A1 (en) * 2018-08-08 2020-02-13 Cedars-Sinai Medical Center Compositions and methods for treating cancer and autoimmune diseases
CN114007535A (zh) 2019-04-18 2022-02-01 盖乐世公司 用于治疗异常组织的装置、系统和方法
CA3147592A1 (en) 2019-07-16 2021-01-21 Galary, Inc. Treatment of the reproductive tract with pulsed electric fields
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
CN115348844A (zh) 2020-04-08 2022-11-15 盖能适治疗股份有限公司 脉冲电场波形操作和使用
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
WO2023153876A1 (ko) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
CA3248580A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US20030049696A1 (en) 2001-06-07 2003-03-13 Norment Anne M. Regulatory T cells and uses thereof
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
CN1798502A (zh) * 2003-05-30 2006-07-05 南佛罗里达大学 治疗恶性肿瘤的方法
US8802643B1 (en) 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
US8101169B2 (en) 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
US7923251B2 (en) 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
WO2007120368A2 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
JPWO2010030002A1 (ja) * 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
CN104245719B (zh) * 2011-12-12 2016-09-14 宾夕法尼亚大学托管会 包含改进的il-12基因构建体的组合物和疫苗、免疫治疗剂及其使用方法
US20180000895A1 (en) * 2015-01-09 2018-01-04 Oncosec Medical Incorporated Method for the treatment of malignancies

Also Published As

Publication number Publication date
EP3799879B1 (en) 2025-06-04
JP2022137203A (ja) 2022-09-21
JP2018504403A (ja) 2018-02-15
US20180000895A1 (en) 2018-01-04
CA2973390A1 (en) 2016-07-14
DK3242947T3 (da) 2020-08-03
ES2809734T3 (es) 2021-03-05
MX383277B (es) 2025-03-13
EP3242947A1 (en) 2017-11-15
JP2021008481A (ja) 2021-01-28
EP3242947A4 (en) 2018-08-08
MX2017009044A (es) 2018-01-11
EP3242947B1 (en) 2020-05-27
WO2016112359A1 (en) 2016-07-14
JP7111384B2 (ja) 2022-08-02
EP3799879A1 (en) 2021-04-07

Similar Documents

Publication Publication Date Title
GB2604416B (en) Tumor infiltating lymphocytes and methods of therapy
IL259783A (en) Methods of treatment of malignant diseases
GB2557123B (en) Modified cells and methods of therapy
IL260959A (en) Gene therapy for the treatment of mucoid polysaccharomyces type i
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL256224B (en) Combined therapy for cancer treatment
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
IL250960B (en) Combined treatment of sinecriviroc for the treatment of leprosy
SMT201900176T1 (it) Terapia con mrna per il trattamento di malattie oculari
IL258521A (en) Combination of treatments for cancer treatment
HUE069690T2 (hu) Génterápia
GB201403260D0 (en) Treatment of retinal degeneration using gene therapy
IL258005A (en) Methods and materials for gene therapy for beta-4,1-en.-acetylgalactosaminyltransferase 2
HUE056570T2 (hu) Génterápia
SG10202100632WA (en) Gene therapy for the treatment of aldehyde dehydrogenase deficiency
SG11201605745VA (en) Targeting clptm1l for treatment and prevention of cancer
IL266726A (en) Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions
GB201511159D0 (en) Controlled cell delivery vehicle and treatment of tumours
GB201701968D0 (en) Gene therapy
HK40006035A (zh) 使用过继细胞疗法治疗b细胞恶性肿瘤的方法
GB201416605D0 (en) Combination therapy to reduce the risk of and to treat cancer
GB201616821D0 (en) Gene therapy
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201612105D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy